

Jean-Charles Soria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2201611/publications.pdf>

Version: 2024-02-01

329
papers

50,317
citations

4388

86
h-index

1634

215
g-index

361
all docs

361
docs citations

361
times ranked

54604
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
2	Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung/IFCT 1301 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4018-4026.	7.0	4
3	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	4.2	12
4	Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. <i>Cancer Discovery</i> , 2021, 11, 233-236.	9.4	169
5	Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 193-201.	2.6	10
6	Circulating T-cell Immunosenescence in Patients with Advanced Non-Small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
7	Interventional Radiology for Local Immunotherapy in Oncology. <i>Clinical Cancer Research</i> , 2021, 27, 2698-2705.	7.0	26
8	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 826-838.	2.8	5
9	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
10	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	9.4	20
11	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	9.4	107
12	José Pepe-Baselga, MD, PhD: In Memoriam (1959-2021). <i>Cancer Discovery</i> , 2021, 11, 1614-1616.	9.4	0
13	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 709-718.	2.1	5
14	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. <i>Cancer Research</i> , 2021, 81, 2888-2902.	0.9	66
15	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study. <i>American Journal of Hematology</i> , 2021, 96, E376-E379.	4.1	2
16	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	11.2	31
17	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	28.4	150
18	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1039-1041.	16.8	2

#	ARTICLE	IF	CITATIONS
19	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	13.2	173
20	Late phase 1 studies: concepts and outcomes. <i>Lancet Oncology</i> , The, 2021, 22, e446-e455.	10.7	2
21	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 831-843.	2.6	71
22	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
23	A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1229-1236.	7.0	43
24	An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 498-508.	5.4	27
25	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	27.0	1,725
26	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020, 6, 1461-1471.	1.8	44
27	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
28	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	13.2	98
29	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	1.1	10
30	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	7.0	23
31	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100023.	1.1	11
32	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	2.8	21
33	Challenges in lung cancer therapy during the COVID-19 pandemic. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 542-544.	10.7	88
34	Optimizing oncolytic virotherapy in cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 689-706.	46.4	325
35	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	12.0	160
36	Inhibition of the Nkp44-PCNA Immune Checkpoint Using a mAb to PCNA. <i>Cancer Immunology Research</i> , 2019, 7, 1120-1134.	3.4	26

#	ARTICLE	IF	CITATIONS
37	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	30.7	362
38	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 975-981.	6.4	61
39	First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1057-1063.	2.3	16
40	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	2.9	101
41	Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. <i>Clinical Cancer Research</i> , 2019, 25, 5441-5448.	7.0	217
42	The "Guardian of the Genome" An Old Key to Unlock the ERCC1 Issue. <i>Clinical Cancer Research</i> , 2019, 25, 2369-2371.	7.0	2
43	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2691-2698.	7.0	78
44	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
45	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	8.2	222
46	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 130, 612-624.	8.2	27
47	MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 152-155.	1.4	0
48	A novel antibody-based approach to detect the functional ERCC1-202 isoform. <i>DNA Repair</i> , 2018, 64, 34-44.	2.8	7
49	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018, 24, 3292-3298.	7.0	41
50	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2018, 19, 649-659.	10.7	450
51	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. <i>British Journal of Cancer</i> , 2018, 118, 344-352.	6.4	7
52	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	4.5	62
53	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 26-27.	0.4	7
54	Osimertinib in EGFR Mutation-Positive Advanced NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 1261-1263.	27.0	20

#	ARTICLE	IF	CITATIONS
55	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018, 36, 62-74.	2.6	3
56	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
57	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 619-628.	2.6	7
58	Are phase I trials safe for older patients?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 87-92.	1.0	4
59	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	27.0	3,530
60	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	1.6	223
61	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	27.6	304
62	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. <i>British Journal of Cancer</i> , 2018, 119, 937-939.	6.4	7
63	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
64	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	2.8	11
65	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1180-1191.	10.7	811
66	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 153-162.	2.0	17
67	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	7.1	53
68	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. <i>PLoS Computational Biology</i> , 2018, 14, e1005965.	3.2	191
69	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 1671-1687.	8.2	19
70	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
71	Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 2001-2001.	1.4	0
72	Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4110-4110.	1.4	0

#	ARTICLE	IF	CITATIONS
73	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2017, 389, 917-929.	13.7	919
74	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <i>Cancer Treatment Reviews</i> , 2017, 55, 83-95.	7.7	58
75	<i>JAK</i> Mutations as Escape Mechanisms to Anti-“PD-1 Therapy. <i>Cancer Discovery</i> , 2017, 7, 128-130.	9.4	24
76	MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S384-S385.	1.1	6
77	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1257-1265.	2.3	25
78	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-“Small Cell Lung Cancer Patients. <i>Cancer Research</i> , 2017, 77, 2222-2230.	0.9	64
79	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. <i>British Journal of Cancer</i> , 2017, 116, 1505-1512.	6.4	25
80	The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. <i>Genetics in Medicine</i> , 2017, 19, 683-690.	2.4	24
81	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 5366-5373.	7.0	109
82	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	9.4	554
83	SC05.02 Novel Cytotoxic Drugs in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S85-S86.	1.1	0
84	P2.03b-050 Prognostic Value of HLA-A2 Status in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S965-S966.	1.1	0
85	P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1176-S1177.	1.1	2
86	P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1186-S1187.	1.1	1
87	P3.02b-102 Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1254-S1255.	1.1	3
88	P3.02c-031 Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1291-S1292.	1.1	0
89	OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S265-S266.	1.1	0
90	Otorhinolaryngological Toxicities of New Drugs in Oncology. <i>Advances in Therapy</i> , 2017, 34, 866-894.	2.9	1

#	ARTICLE	IF	CITATIONS
91	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	2.8	132
92	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
93	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6411-6420.	7.0	43
94	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	1.4	10
95	Prognostic factors and outcome of patients with hematological malignancies in phase I trials. <i>Anti-Cancer Drugs</i> , 2017, 28, 540-545.	1.4	1
96	Patient-reported tolerability of adverse events in phase 1 trials. <i>ESMO Open</i> , 2017, 2, e000148.	4.5	20
97	Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. <i>Annals of Oncology</i> , 2017, 28, iii145.	1.2	12
98	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017, 23, 1920-1928.	7.0	960
99	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. <i>Investigational New Drugs</i> , 2017, 35, 79-86.	2.6	3
100	First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2017, 23, 908-917.	7.0	149
101	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2423-2432.	7.0	50
102	A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 1177-1185.	7.0	23
103	Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, e1-e3.	1.1	4
104	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188174.	2.5	85
105	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	4.5	87
106	A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. <i>Oncotarget</i> , 2017, 8, 56199-56209.	1.8	8
107	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017, 8, 108786-108801.	1.8	22
108	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 25549-25557.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Medicine, 2016, 13, e1002201.	8.4	300
110	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS ONE, 2016, 11, e0154895.	2.5	10
111	An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1) Tj ETQq1 1 0.784314 rgBT tumors. Anti-Cancer Drugs, 2016, 27, 342-348.	1.4	12
112	Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers. Clinical Cancer Research, 2016, 22, 5983-5991.	7.0	124
113	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	7.0	182
114	Patients aged over 75 years enrolled in Phase I clinical trials: the <i>G</i> ustave <i>R</i> oussy experience. International Journal of Cancer, 2016, 138, 875-880.	5.1	5
115	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study. Journal of Thoracic Oncology, 2016, 11, S309-S310.	1.1	3
116	MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer. Cancer Biomarkers, 2016, 17, 323-333.	1.7	7
117	Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF -Mutated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, e109-e112.	1.1	27
118	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369.	1.7	0
119	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	27.6	831
120	P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. Journal of Thoracic Oncology, 2016, 11, S241-S242.	1.1	18
121	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
122	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. Cancer Research, 2016, 76, 5954-5961.	0.9	16
123	Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anti-Cancer Drugs, 2016, 27, 1021-1027.	1.4	7
124	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. Journal of Thoracic Oncology, 2016, 11, 850-861.	1.1	78
125	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	1.1	31
126	Update to Rociletinib Data with the RECIST Confirmed Response Rate. New England Journal of Medicine, 2016, 374, 2296-2297.	27.0	72

#	ARTICLE	IF	CITATIONS
127	Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, S37.	1.1	0
128	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	13.7	790
129	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	7.0	103
130	Novel therapeutic targets in advanced urothelial carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 106-115.	4.4	45
131	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	1.6	300
132	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. <i>Cell Cycle</i> , 2016, 15, 295-302.	2.6	23
133	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. <i>Journal of Thoracic Oncology</i> , 2016, 11, e21-e23.	1.1	8
134	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 511-525.	2.8	212
135	A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. <i>Investigational New Drugs</i> , 2016, 34, 397-398.	2.6	22
136	Assessment of <i>EGFR</i> Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016, 22, 2386-2395.	7.0	169
137	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016, 152, 45.	4.1	539
138	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>Oncolmmunology</i> , 2016, 5, e1071008.	4.6	545
139	Dendritic cell-derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 1224-1232.	8.2	427
140	LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy. <i>Chest</i> , 2015, 148, 585A.	0.8	0
141	Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-“Small Cell Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2015, 10, e72-e73.	1.1	5
142	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , 2015, 123, 307-314.	2.9	16
143	Immune Checkpoint Modulation for Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2256-2262.	7.0	90
144	Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors. <i>Oncologist</i> , 2015, 20, 245-246.	3.7	32

#	ARTICLE	IF	CITATIONS
145	10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient. <i>European Respiratory Journal</i> , 2015, 46, 280-282.	6.7	11
146	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. <i>Cancer Biomarkers</i> , 2015, 15, 151-156.	1.7	12
147	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1605-1629.	3.1	25
148	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 157-163.	0.8	28
149	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317.	7.0	230
150	VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. <i>Cancer Research</i> , 2015, 75, 1187-1190.	0.9	92
151	Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. <i>Clinical Cancer Research</i> , 2015, 21, 1896-1903.	7.0	199
152	First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation. <i>Clinical Lung Cancer</i> , 2015, 16, e259-e261.	2.6	5
153	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	10.7	389
154	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	10.7	353
155	Targeting FGFR Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2684-2694.	7.0	399
156	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015, 33, 3439-3446.	1.6	234
157	Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	27.0	615
158	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
159	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 108-117.	2.4	26
160	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 1413-1420.	6.4	18
161	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3401-3408.	1.6	324
162	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	1.1	138

#	ARTICLE	IF	CITATIONS
163	Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. <i>Blood</i> , 2015, 126, 473-473.	1.4	37
164	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14139-14152.	1.8	22
165	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. <i>Chinese Clinical Oncology</i> , 2015, 4, 48.	1.2	5
166	Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 823-833.	2.4	12
167	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	27.8	4,342
168	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014, 9, 144-153.	1.1	83
169	Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?. <i>Journal of Thoracic Oncology</i> , 2014, 9, 7-17.	1.1	31
170	Implementing precision medicine initiatives in the clinic. <i>Current Opinion in Oncology</i> , 2014, 26, 340-346.	2.4	17
171	TGR Analysis in Phase I Clinical Trialsâ€™ Response. <i>Clinical Cancer Research</i> , 2014, 20, 2497-2497.	7.0	3
172	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2014, 20, 246-252.	7.0	144
173	Genomes in the clinic: the Gustave Roussy Cancer Center experience. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 99-106.	3.3	10
174	Dysphonia induced by anti-angiogenic compounds. <i>Investigational New Drugs</i> , 2014, 32, 774-782.	2.6	19
175	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
176	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. <i>Clinical Cancer Research</i> , 2014, 20, 265-272.	7.0	36
177	Pharmacokinetics of pazopanib administered in combination with bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1189-1196.	2.3	17
178	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. <i>Investigational New Drugs</i> , 2014, 32, 312-322.	2.6	6
179	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 1188-1196.	2.6	20
180	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i>â€™RAF</i> Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261.	7.0	60

#	ARTICLE	IF	CITATIONS
181	Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas. <i>Clinical Lung Cancer</i> , 2014, 15, 124-130.	2.6	19
182	Customized Adjuvant Phase II Trial in Patients With Non-“Small-Cell Lung Cancer: IFCT-0801 TASTE. <i>Journal of Clinical Oncology</i> , 2014, 32, 1256-1261.	1.6	66
183	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	7.7	51
184	LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, e62-e63.	1.1	29
185	PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?. <i>Current Pharmaceutical Design</i> , 2014, 20, 3875-3882.	1.9	14
186	A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience. <i>Blood</i> , 2014, 124, 1759-1759.	1.4	0
187	Prognostic Factors and Outcome of Patients with Hematological Malignancies in Phase I Trials: The Gustave Roussy Scoring System. <i>Blood</i> , 2014, 124, 3504-3504.	1.4	0
188	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4080-4088.	3.6	72
189	Management of non-small-cell lung cancer: recent developments. <i>Lancet, The</i> , 2013, 382, 709-719.	13.7	658
190	Quantitative Proteomics Profiling of Primary Lung Adenocarcinoma Tumors Reveals Functional Perturbations in Tumor Metabolism. <i>Journal of Proteome Research</i> , 2013, 12, 3934-3943.	3.7	40
191	Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2167-2172.	1.6	170
192	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 437-446.	2.5	70
193	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma. <i>Investigational New Drugs</i> , 2013, 31, 1530-1538.	2.6	22
194	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 1257-1268.	7.0	117
195	19q13-ERCC1 Gene Copy Number Increase in Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 549-557.	2.6	9
196	Translating metastasis-related biomarkers to the clinic-“progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 169-179.	27.6	40
197	ERCC1 Isoform Expression and DNA Repair in Non-“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	27.0	342
198	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. <i>Cell Cycle</i> , 2013, 12, 877-883.	2.6	57

#	ARTICLE	IF	CITATIONS
199	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 479-492.	5.9	46
200	What can be done for patients with NSCLC without druggable targets?. <i>Lancet Oncology</i> , The, 2013, 14, 191-192.	10.7	1
201	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. <i>Oncolmmunology</i> , 2013, 2, e23079.	4.6	18
202	Phase I clinical trial combining imatinib mesylate and IL-2. <i>Oncolmmunology</i> , 2013, 2, e23080.	4.6	29
203	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 647-654.	2.6	16
204	Cisplatin Resistance Associated with PARP Hyperactivation. <i>Cancer Research</i> , 2013, 73, 2271-2280.	0.9	143
205	IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1213-1222.	4.1	40
206	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. <i>Journal of Clinical Oncology</i> , 2013, 31, 817-818.	1.6	7
207	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. <i>Cell Cycle</i> , 2013, 12, 3298-3306.	2.6	37
208	Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2173-2181.	1.6	270
209	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. <i>Clinical Cancer Research</i> , 2013, 19, 4315-4325.	7.0	32
210	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4832-4842.	7.0	43
211	Europe Does It Better: Molecular Testing across a National Health Care System—The French Example. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 332-337.	3.8	18
212	Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells. <i>Cancer Discovery</i> , 2012, 2, 434-449.	9.4	49
213	Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2012, 30, 996-1004.	1.6	68
214	Vascular disrupting agents. <i>Current Opinion in Oncology</i> , 2012, 24, 305-315.	2.4	37
215	Skin Tumors Induced by Sorafenib; Paradoxical RAS Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i> . <i>Clinical Cancer Research</i> , 2012, 18, 263-272.	7.0	119
216	Loss-of-function alleles of <i>P2RX7</i> and <i>TLR4</i> fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolmmunology</i> , 2012, 1, 271-278.	4.6	36

#	ARTICLE	IF	CITATIONS
217	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4806-4819.	7.0	136
218	Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2012, 18, 2443-2451.	7.0	274
219	Trastuzumab-Induced Cardiotoxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 183-184.	1.3	5
220	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1423-1431.	1.1	9
221	Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1594-1601.	1.1	35
222	Maintenance Therapy and Advanced Non-Small-Cell Lung Cancer: A Skeptic's View. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1331-1336.	1.1	24
223	A Comparative and Integrative Approach Identifies <i>ATPase Family, AAA Domain Containing 2</i> as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 5606-5616.	7.0	68
224	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. <i>Molecular Cell</i> , 2012, 48, 322-324.	9.7	0
225	Minimal residual disease in solid neoplasia: New frontier or red-herring?. <i>Cancer Treatment Reviews</i> , 2012, 38, 101-110.	7.7	19
226	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012, 38, 416-430.	7.7	114
227	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
228	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 144-155.	27.6	96
229	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 391-395.	2.6	128
230	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 301-313.	4.4	76
231	Circulating Tumor Cells in Lung Cancer. <i>Acta Cytologica</i> , 2012, 56, 655-660.	1.3	65
232	Tumour molecular profiling for deciding therapy—the French initiative. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 479-486.	27.6	81
233	p38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. <i>Cancer</i> , 2012, 118, 5015-5025.	4.1	22
234	Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. <i>Investigational New Drugs</i> , 2012, 30, 1116-1120.	2.6	6

#	ARTICLE	IF	CITATIONS
235	Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. <i>Investigational New Drugs</i> , 2012, 30, 611-615.	2.6	38
236	Implications of personalized medicine—perspective from a cancer center. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 177-183.	27.6	52
237	ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. <i>American Journal of Pathology</i> , 2011, 178, 69-78.	3.8	59
238	Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3783-3790.	1.6	76
239	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 53-61.	2.3	18
240	Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. <i>Cancer</i> , 2011, 117, 1288-1295.	4.1	90
241	Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1236-1238.	1.6	65
242	Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4442-4451.	1.6	227
243	Reply to A.H. Fischer et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3332-3333.	1.6	16
244	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae. <i>Cell Cycle</i> , 2011, 10, 118-126.	2.6	10
245	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. <i>Cell Cycle</i> , 2011, 10, 963-970.	2.6	48
246	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. <i>Cancer Research</i> , 2011, 71, 661-665.	0.9	144
247	Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL. <i>Journal of Immunology</i> , 2011, 187, 5532-5539.	0.8	37
248	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1728-1735.	1.6	120
249	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. <i>Clinical Cancer Research</i> , 2011, 17, 5562-5572.	7.0	56
250	Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials. <i>PLoS ONE</i> , 2011, 6, e16633.	2.5	13
251	Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells. <i>PLoS ONE</i> , 2011, 6, e26073.	2.5	41
252	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 341-345.	1.3	39

#	ARTICLE	IF	CITATIONS
253	MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1206-1215.	7.0	89
254	Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 369-375.	1.1	38
255	Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. <i>Investigational New Drugs</i> , 2010, 28, 102-105.	2.6	1
256	Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib) Tj ETQq0 0 0 rgBT /Overlock 10 New Drugs, 2010, 28, 199-202.	2.6	48
257	Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. <i>Investigational New Drugs</i> , 2010, 28, 350-352.	2.6	1
258	Reversible cardiogenic shock following 5-Fluorouracil infusion. <i>Investigational New Drugs</i> , 2010, 28, 531-533.	2.6	3
259	Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors. <i>Investigational New Drugs</i> , 2010, 28, 884-886.	2.6	17
260	Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 94-109.	4.4	38
261	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 367-380.	27.6	94
262	Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1265-1273.	4.1	15
263	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 358-368.	4.1	44
264	The Evolving Role of Histology in the Management of Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5311-5320.	1.6	247
265	Validation of ERCC1-XPF Immunodetection “ Letter. <i>Cancer Research</i> , 2010, 70, 3851-3852.	0.9	19
266	Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis. <i>Clinical Cancer Research</i> , 2010, 16, 2979-2988.	7.0	34
267	The Role of Anti-“Epidermal Growth Factor Receptor and Anti-“Vascular Endothelial Growth Factor Therapies in the Treatment of Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 82-90.	2.6	38
268	Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. <i>Anticancer Research</i> , 2010, 30, 3869-78.	1.1	16
269	Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib. <i>Journal of Clinical Oncology</i> , 2009, 27, e59-e61.	1.6	152
270	Differential Expression of Biomarkers in Men and Women. <i>Seminars in Oncology</i> , 2009, 36, 553-565.	2.2	52

#	ARTICLE	IF	CITATIONS
271	Wound healing delay after central venous access following DCF/VEGF-trap therapy. <i>Investigational New Drugs</i> , 2009, 27, 583-585.	2.6	5
272	QT interval prolongation among patients treated with angiogenesis inhibitors. <i>Targeted Oncology</i> , 2009, 4, 89-97.	3.6	30
273	Concomitant chemo-radiotherapy in clinical trials: To promote step by step rational development. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 206-215.	4.4	6
274	Are RAS mutations predictive markers of resistance to standard chemotherapy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 528-534.	27.6	79
275	Pemetrexed-Induced Pneumonitis: A Case Report. <i>Clinical Lung Cancer</i> , 2009, 10, 364-366.	2.6	14
276	Expression of Cell Cycle Biomarkers and Telomere Length in Papillary Thyroid Carcinoma: A Comparative Study Between Radiation-Associated and Spontaneous Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 1-8.	1.3	9
277	Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1212-1220.	1.1	97
278	IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1126-1135.	1.1	51
279	Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1504-1510.	1.1	15
280	Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 99-117.	4.4	77
281	Gene expression profiling of non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 167-178.	3.1	28
282	Potential of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. <i>International Immunology</i> , 2008, 20, 801-810.	4.0	27
283	Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 610-618.	4.3	22
284	Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers. <i>Clinical Cancer Research</i> , 2008, 14, 4096-4102.	7.0	20
285	Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 268-278.	4.3	96
286	Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 677-679.	1.1	18
287	Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , 2007, 13, 3892-3898.	7.0	73
288	Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 3855-3859.	7.0	122

#	ARTICLE	IF	CITATIONS
289	Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4825-4831.	7.0	36
290	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , 2007, 25, 2735-2740.	1.6	107
291	P3-071: Respiratory symptoms improvement in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib: Quality of Life analysis of the IFCT-0401 trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, S708.	1.1	1
292	QTc Monitoring During a Phase I Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 106-112.	1.3	7
293	ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 284-289.	2.6	79
294	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. <i>Molecular Cell</i> , 2007, 28, 624-637.	9.7	116
295	D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC. <i>Journal of Thoracic Oncology</i> , 2007, 2, S397-S398.	1.1	7
296	Telomerase expression in lung preneoplasia and neoplasia. <i>International Journal of Cancer</i> , 2007, 120, 1835-1841.	5.1	70
297	Mutations in JAK2 ^{V617F} homologous domain of JAK genes are uncommon in solid tumors. <i>International Journal of Cancer</i> , 2007, 121, 2113-2115.	5.1	4
298	Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. <i>Anticancer Research</i> , 2007, 27, 547-55.	1.1	51
299	Aquaporin 1 Is Overexpressed in Lung Cancer and Stimulates NIH-3T3 Cell Proliferation and Anchorage-Independent Growth. <i>American Journal of Pathology</i> , 2006, 168, 1345-1353.	3.8	150
300	DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 983-991.	27.0	1,611
301	Telomeres and telomerase as targets for anticancer drug development. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 191-214.	4.4	85
302	Cyclooxygenase-2 as a target for anticancer drug development. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 51-64.	4.4	186
303	Response to Erlotinib in First-Line Treatment of Non-Small-Cell Lung Cancer in a White Male Smoker with Squamous-Cell Histology. <i>Clinical Lung Cancer</i> , 2006, 8, 214-216.	2.6	11
304	Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. <i>International Journal of Cancer</i> , 2006, 118, 1068-1069.	5.1	19
305	Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study. <i>Clinical Cancer Research</i> , 2006, 12, 6049-6055.	7.0	197
306	Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 476-477.	4.3	0

#	ARTICLE	IF	CITATIONS
307	Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2005, 32, 279-283.	2.2	10
308	NK Cells Infiltrating a MHC Class I-Deficient Lung Adenocarcinoma Display Impaired Cytotoxic Activity toward Autologous Tumor Cells Associated with Altered NK Cell-Trigginging Receptors. <i>Journal of Immunology</i> , 2005, 175, 5790-5798.	0.8	69
309	Cutaneous side-effects of kinase inhibitors and blocking antibodies. <i>Lancet Oncology</i> , The, 2005, 6, 491-500.	10.7	527
310	Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 2547-2551.	7.0	14
311	Nuclear Localization of Apoptosis Protease Activating Factor-1 Predicts Survival after Tumor Resection in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5665-5669.	7.0	26
312	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 470.	7.4	305
313	Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer. <i>Seminars in Radiation Oncology</i> , 2004, 14, 315-321.	2.2	7
314	Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. <i>Annals of Surgical Oncology</i> , 2004, 11, 45-51.	1.5	44
315	Aquaporin expression in human lymphocytes and dendritic cells. <i>American Journal of Hematology</i> , 2004, 75, 128-133.	4.1	76
316	Involvement of aquaporins in colorectal carcinogenesis. <i>Oncogene</i> , 2003, 22, 6699-6703.	5.9	175
317	Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. <i>Oncogene</i> , 2003, 22, 7123-7129.	5.9	60
318	Telomere-driven genomic instability in cancer cells. <i>Cancer Letters</i> , 2003, 194, 173-182.	7.2	69
319	Chemoprevention of lung cancer. <i>Lancet Oncology</i> , The, 2003, 4, 659-669.	10.7	52
320	Retinoic Acid Receptor α and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 165-168.	6.3	20
321	Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1785-91.	7.0	30
322	Breast metastasis from lung adenocarcinoma: a case report. <i>Anticancer Research</i> , 2003, 23, 1825-6.	1.1	15
323	Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. <i>Anticancer Research</i> , 2003, 23, 4885-90.	1.1	13
324	Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. <i>Cancer Research</i> , 2002, 62, 351-5.	0.9	103

#	ARTICLE	IF	CITATIONS
325	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. <i>Clinical Cancer Research</i> , 2002, 8, 1178-84.	7.0	312
326	hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2883-9.	7.0	56
327	DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. <i>Investigational New Drugs</i> , 2000, 18, 123-137.	2.6	28
328	Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2293-2300.	1.6	61
329	Telomerase Activity in Cancer. <i>Advances in Anatomic Pathology</i> , 1998, 5, 86-94.	4.3	9